The Cannabis Insurance Crisis: Why a $30 Billion Industry Still Can't Get Proper Coverage

The American cannabis industry generates roughly $30 billion in annual revenue, employs nearly 450,000 people, and operates in some of the country's most expensive real estate markets. By any conventional measure, it's a mature, substantial industry. But try to insure a cannabis business in 2026, and you'll discover just how unconventional the industry remains.

Despite the Justice Department's landmark decision in April to place state-licensed medical cannabis in Schedule III of the Controlled Substances Act, cannabis businesses continue to face an insurance landscape that would be unrecognizable to operators in any other sector of comparable size. Premiums are rising. Policy limits are inadequate. Carrier participation remains limited. And in what might be the most absurd detail of all, many cannabis businesses still have to pay their insurance premiums in cash — because the same banking challenges that plague the rest of the industry extend to the companies trying to protect it.

The Core Problem: Federal Uncertainty

Insurance is fundamentally a business of risk assessment, and insurers are among the most heavily regulated businesses in America. State insurance departments oversee policy language, capitalization requirements, and claims practices. Federal regulators have jurisdiction over some insurance products. And all of these regulators take their cues from federal law.

For decades, the fact that cannabis was a Schedule I controlled substance created an impossible paradox: state-legal businesses needed insurance, but writing a policy to cover a federally illegal activity created potential liability for the insurer itself. Could an insurance company be prosecuted for aiding and abetting a Schedule I drug operation by providing coverage? The answer was always "probably not," but "probably not" isn't the kind of certainty that insurance company general counsels find comforting.

Rescheduling to Schedule III has changed the legal calculus somewhat, but the change is narrower than many hoped. The April order applies only to FDA-approved cannabis products and state-licensed medical cannabis — not recreational products, which account for the majority of industry revenue. This means that insurers covering adult-use cannabis operations are still, technically, covering activity that remains illegal under federal law's broadest interpretation.

Until Congress passes comprehensive cannabis reform or the DEA's forthcoming hearing results in broader rescheduling, the federal uncertainty that drives the insurance crisis will persist.

What Coverage Gaps Actually Look Like

The gap between what cannabis businesses need and what they can actually obtain is significant across every category of commercial insurance.

General liability and commercial insurance policies are typically capped at $1 million per occurrence and $2 million in aggregate — limits that many operators describe as woefully inadequate. A single product liability lawsuit or a significant property loss could easily exceed those limits, leaving the business exposed to potentially devastating out-of-pocket costs. In comparable industries, businesses routinely carry $5 million or $10 million in coverage.

Property and crop insurance is another major gap. For cultivators, most available policies cover only named perils — specific, listed events like fire or theft — rather than comprehensive crop failure. A disease outbreak, a pest infestation, or an environmental contamination event could wipe out a harvest with no insurance safety net.

Product liability coverage remains expensive and limited. With the Murray v. Cresco RICO lawsuit now in the courts, alleging that major MSOs concealed health risks from consumers, product liability exposure across the industry is rising rapidly. Insurers see this and price accordingly — or simply decline to offer the coverage at all.

Workers' compensation presents its own challenges. Cannabis processing facilities involve industrial equipment, chemical solvents, and repetitive manual labor, all of which generate claims. Impairment in the workplace — a unique consideration for an industry whose employees work with a psychoactive substance — adds another layer of risk that traditional workers' comp carriers may not be comfortable underwriting.

Directors and officers liability, errors and omissions, cyber liability, employment practices liability — in every category, cannabis businesses face either limited availability, elevated premiums, or both.

The Cash Payment Absurdity

Perhaps the most telling detail of the cannabis insurance crisis is the payment mechanism. Because many cannabis businesses lack access to traditional banking services, they must pay insurance premiums in cash. This means armored car deliveries to insurance offices, money orders, and convoluted payment arrangements that add cost and complexity to an already difficult process.

For insurers, accepting cash payments from cannabis businesses creates its own compliance headaches. Anti-money laundering regulations, suspicious activity reporting requirements, and internal compliance policies all make cash transactions more expensive and risky to process. Some carriers simply refuse to accept cash payments, effectively excluding cannabis businesses from coverage regardless of how attractive the risk might otherwise be.

The Senate Banking Committee has acknowledged this broader problem. Chairman Tim Scott described the cannabis industry's financial services access issues as a "quandary" and suggested that a solution is forthcoming, though no specific legislation has been introduced as of May 2026.

Schedule III: Partial Relief at Best

The rescheduling order has provided some tangible benefits. Medical cannabis operators who successfully register with the DEA can now deduct ordinary business expenses — rent, payroll, marketing — that were previously disallowed under Section 280E of the tax code. This financial relief will make medical operations more profitable, which in turn makes them more attractive to insurers.

Rescheduling has also prompted several new specialty carriers to enter the cannabis insurance market, attracted by the perception that federal risk has diminished. More carriers means more competition, which should theoretically bring premiums down. But the entry of new carriers has been offset by rising claim frequency and severity, particularly in product liability, keeping the overall market tight.

The most significant impact of rescheduling on insurance may come from the Drug Enforcement Administration's ongoing process to extend Schedule III classification to all cannabis — not just medical. If the DEA's June 29 hearing results in broader rescheduling, the federal uncertainty that has constrained insurance availability for years would largely evaporate. Traditional carriers — the Hartfords and Chubbs and Zurichs of the world — might finally enter the cannabis space in force, bringing the capacity, sophistication, and competitive pricing that the industry desperately needs.

But that hearing hasn't happened yet. And anyone who has watched cannabis policy move through federal institutions knows that timelines are suggestions, not commitments.

What Smart Operators Are Doing Now

In the absence of a perfect insurance market, the most sophisticated cannabis operators are taking several proactive steps.

Risk mitigation has become a core business function, not an afterthought. This means comprehensive safety programs, detailed standard operating procedures, rigorous product testing beyond what regulators require, and defensive labeling practices that clearly communicate risks to consumers. Every lawsuit prevented is worth more than any insurance policy.

Some operators are forming captive insurance companies — essentially self-insurance vehicles that allow a business to pool its own premiums, control its claims process, and potentially achieve coverage that the open market won't provide. Captives require significant upfront capital and regulatory expertise, but for mid-to-large-scale operators, they offer a degree of control and customization that commercial policies can't match.

Industry associations are also playing a larger role. The Cannabis Credit Authority (CCA 2.0), which launched in early 2026 as the industry's first credit bureau, is providing the data infrastructure that insurers need to underwrite cannabis risks more accurately. Better data means better pricing, which benefits the entire ecosystem.

And some operators are simply accepting elevated risk as a cost of doing business. They carry whatever coverage they can obtain, self-insure the gaps, and factor the residual exposure into their business plans. It's not ideal, but in an industry where "ideal" is rarely an option, pragmatism has its own value.

The Road Ahead

The cannabis insurance crisis won't be resolved by any single event — not rescheduling, not banking reform, not a court ruling. It will be resolved incrementally, as federal law gradually catches up to state-level reality, as more actuarial data becomes available, and as traditional carriers become comfortable with a risk they've been avoiding for decades.

In the meantime, cannabis businesses will continue to pay more for less coverage than virtually any other industry of comparable size. It's one of the quiet costs of prohibition's long shadow — a tax that doesn't appear on any balance sheet but affects every cannabis company in America.

For consumers, the insurance crisis matters too. Inadequate coverage means that when things go wrong — a contaminated product, a workplace accident, a data breach — there may not be enough financial backstop to make affected parties whole. That's a risk we all carry, whether we realize it or not.

Want to find a licensed dispensary near you? Browse Budpedia's cannabis dispensary directory — 7,400+ verified retailers with menus, deals, and hours across every legal state.